Eli Lilly and Company launched Symbyax in the U.S.
On Apr. 19, 2004, Eli Lilly and Company launched Symbyax in the U.S., the first and only Food and Drug Administration (FDA)-approved treatment of acute depressive episodes in Bipolar I Disorder and for treatment resistant depression.
In 2013, the FDA approved Symbyax for the treatment of acute depressive episodes associated with Bipolar I Disorder in patients 10 to 17 years of age.
Tags:
Source: U.S. Food and Drug Administration
Credit:
